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ABSTRACT
HIV-1 Tat interactions with opioids are modulated by progesterone and estradiol
(Under the direction of Dr. Jason Paris)

HIV infection and combined substance abuse are comorbid epidemics. Previous studies
show that concurrent opioid drug use may potentiate HIV-1-mediated neurotoxicity partly
via interactions with opioids. Preclinical studies suggest that the HIV-1 trans-activator of
transcription (Tat), an HIV regulatory protein, can synergize with opioids to exacerbate its
already neurotoxic effects. However, its interactions with clinical opioids, such as
oxycodone, have yet to be elucidated. Additionally, Tat disrupts a number of systems
including the dopaminergic system, which contribute to its capacity to potentiate the
rewarding effects of abused drugs. Although the neurotoxic effects of Tat may be inhibited
by gonadal steroids in vitro, such as estradiol (E2) and progesterone (P4), preclinical work
suggests that estradiol may also potentiate drug reward/reinforcement as well. Little is
known about the behavioral interactions between Tat and E2. In a 2-bottle choice task, we
found that Tat expression in mice significantly increased morphine preference on the first
day of morphine presentation. E2 (0.09 mg/kg, s.c., QOD) significantly increased morphine
consumption, irrespective of Tat expression. Following naloxone-precipitated withdrawal,
Tat or E2 increased jumping behavior. In complementary in vitro experiments, Tat
increased cell death in SH-SY5Y human neuroblastoma cells and oxycodone did not
further potentiate this effect. Irrespective of whether cells were treated with Tat alone or in
combination with oxycodone, any concentration of E2 (1 or 10 nM), or the highest
concentration of P4 (100 nM, but not 10 nM) significantly attenuated Tat-mediated cell
death. These data suggest that E2 may display parallel protective qualities over Tat’s
iv

capacity to potentiate withdrawal and promote cell death. However, caution is warranted
given E2’s capacity to increase opioid self-administration. These data lend further evidence
to support the potential neuroprotective efficacy of gonadal steroid hormone-based
therapeutics and further our understanding of their interactions with HIV-1 and the
clinically-prescribed opioid, oxycodone.
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1. Introduction
1.1. HIV-1 Patients and Neurological Dysfunction
With the introduction of combined antiretroviral therapy (cART), HIV type 1 (HIV1) has transitioned to a chronic disease (Nakagawa et al., 2013). These therapies prove
efficacious in reducing viral load and promoting the recovery of the immune system, thus
increasing the life expectancy of patients with HIV-1 (Li et al., 1998). However, due to
cART’s poor retention within the central nervous system (CNS) and inability to target
latent viral reservoirs, HIV-1 proteins continue to be produced. Some HIV-1 proteins that
are produced from these viral reservoirs are neurotoxic and promote a constellation of
neurological disorders including affective, cognitive, and motor dysfunctions, collectively
termed neuroHIV. Despite the success of cART, approximately 50% of individuals with
HIV-1 suffer from neuroHIV (Tozzi et al., 2007; Simioni et al., 2010). As such, it is
important to elucidate the underlying causes and mechanisms of neuroHIV, to better
understand and treat this phenomenon.
1.2. The Trans-activator of Transcription: An Excitotoxic HIV-1 Protein
Among the soluble HIV-1 proteins that accumulate within the CNS, the HIV-1
trans-activator of transcription (Tat) is among the most toxic, and plays a critical role in
the virus’ propagation in the CNS. HIV-1 Tat is critical in the replication of the virus (Jeang
et al., 1991). Furthermore, findings from in vitro studies suggest that Tat administration is
linked to increased neuronal apoptosis, leading to cellular damage and death (Kruman et
al., 1998). Studies also suggest that HIV-1 Tat neurotoxicity is likely mediated by the
protein’s ability to alter calcium homeostasis (Haughey et al. 1999; Haughey and Mattson,
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2002; Hu, 2016), stimulate glutamate receptors to cause excitotoxic effects (Gras et al.,
2003), and induce oxidative stress (Kruman et al., 1998; Perl and Banki, 2000), which is a
consistent biomarker found in patients with HIV associated dementia (Sacktor et al., 2004).
Moreover, Tat is also suspected to play a role in the synaptodendritic injury that is observed
in HIV-1 patients (Bertrand et al., 2013) which contributes to neurocognitive deficits. As
such, various mechanisms underlie Tat-mediated neuronal dysfunction that likely
contributes to the neuropathology of neuroHIV.
1.3. Neurologic Effects of HIV-1 Tat and Combined Substance Use
HIV-1 infection and combined substance use have become increasingly co-morbid
(Gorman, 1998; Mathers et al., 2008), and a substantial amount of evidence suggest
concurrent HIV-1 infection and combined substance use can increase the prevalence and
severity of neuroHIV among infected patients (Bell et al., 2006). A number of studies also
suggest that the HIV virus’ infiltration and subsequent damage and dysregulation of
structures in dopamine system, a well-known mediator of drug reward and reinforcement
(Kalivas & Volkow, 2005; Koob & Volkow, 2016), may be a contributing factor in the
development and worsening of neuroHIV (Bell et al., 2006; Gaskill et al., 2013).
Interestingly, HIV-1 Tat has been shown to be involved in HIV mediated alterations in the
dopamine system (Fitting et al., 2015). More specifically, in vitro studies show that Tat’s
involvement includes dysregulation of dopamine transporters, and interaction with
dopamine receptors to cause neurotoxicity (Bucci, 2015; Kesby et al., 2018; Midde et al.,
2012; Silvers et al., 2007). Furthermore, addiction studies also suggest that Tat may interact
with psychostimulant drugs of abuse to potentiate their effects. When modeled in animals,
drug self-administration, a key tenet of the addiction cycle, may be enhanced by the
2

presence of Tat. For instance, HIV-1 Tat expression has been shown to potentially increase
the rewarding effects of cocaine in male mice (Paris et al, 2014). Another study suggests
that Tat expression can lead to reward deficits, but increase sensitivity to methamphetamine
related reward enhancements (Kesby et al., 2016). In another study, HIV-1 Tat mice also
displayed increased morphine-conditioned place preference (Gonek et al., 2018).
1.4. Sex Differences in HIV-1 and Substance Abuse-Related Neurological Sequelae
A growing amount of evidence suggests that there is also likely sex difference in
the vulnerability to neurological dysfunction associated with HIV. In the general
population, women tend to be diagnosed with anxiety and depressive disorders more often
than men (McLean et al., 2011). Interestingly, this sex difference is reversed with some
studies suggesting that women with HIV may exhibit a decreased vulnerability to HIVassociated affective disorders (Bing et al., 2001; Lopes et al., 2012) as well as reduced
neurological dysfunction (Cabrera-Muñoz et al., 2012); though, these findings are not
always observed. Some studies report a greater vulnerability among women or do not find
a gender difference (Sewell et al., 2000; Tsao et al., 2004). Some of these effects are
recapitulated in animal models. When exposed to Tat in an in vivo setting, female mice
exhibit less neuronal degeneration and behavioral deficits than do males (Hahn et al.,
2015). Past observations suggest that sex steroid hormones may play a role.
Ovariectomized, Tat expressing, female mice exhibit a decrease in anxiety-like behavior
when administered progesterone (Paris et al., 2014; 2016).
When combined with comorbid substance use, these HIV-1 related neurological
effects can be aggravated. Various studies suggest that there are significant differences in
addiction-related behavior among females and males. However, the literature on addiction
3

has been mainly comprised of research on male models. Studies show that a greater
proportion of men engage in substance abuse compared to women (Becker et al., 2017).
On the other hand, women tend to escalate use of drugs and alcohol to the point of addiction
faster than men (Bobzean et al., 2014). This is also true in animal models, as female rats
acquire cocaine self-administration behaviors faster than male rats (Becker, 2016; Becker
& Koob 2016). Some studies speculate that sex differences in the addiction cycles may be
mediated by sex hormones, such as estradiol and progesterone.
In vivo experiments suggest that estradiol promotes cocaine self-administration in
rats, while progesterone decreased self-administration (Larson et al., 2007). In female
ovariectomized rats, estradiol treatment increases drug-taking behaviors and behavioral
responses to cocaine and amphetamine (Peris et al., 1991; Hu & Becker, 2003). Estradiol’s
effect is thought to be mediated through its ability to alter dopaminergic functioning. For
example, some studies found that estradiol exposure can increase dopamine release in the
striatum (Becker, 1990) within the mesolimbic dopaminergic pathway. Coincidingly,
psychostimulant induced increases of dopamine were enhanced in ovariectomized female
rats when treated with estradiol compared to estradiol treated male rats (Cummings et al.,
2014). However, in vitro studies suggest that estradiol displays neuroprotective qualities
against HIV-1 Tat (Kendall et al., 2005; Salahuddin et al., 2019; Turchan et al., 2001;
Wallace et al., 2006). The behavioral effects of estradiol on opioid reward and
reinforcement in combination with HIV-1 Tat expression have yet to be elucidated.

4

1.5. Opioid use and HIV infection
With opioid drug abuse and opioid prescriptions on the rise in the HIV population
(Williams & Bisaga 2016; Dutta & Roy 2012; Edelman et al., 2012), it is becoming more
pertinent to understand the interactions between the opioids and HIV-1. Studies suggest
that opioid abuse exacerbates the effects of neuroHIV (Anthony et al., 2008). However, the
current literature is discrepant. Some studies suggest that morphine, the prototypical opiate,
may display protective qualities by slowing AIDS progression in non-human primate
models (Donahoe et al., 2009). Other studies suggest that morphine stimulates replication
of viral HIV-1 proteins (Schweitzer et al., 1991), and also interacts with HIV-1 Tat to
potentiate its neurotoxic effects in vitro. Furthermore, evidence suggests that opioid abuse
increases the synaptodendritic degeneration when opioids and HIV-1 Tat are administered
in conjunction in mice (Fitting et al., 2010a; Fitting et al., 2014). Interestingly, oxycodone’s
interaction with HIV-1 proteins has remained under-investigated and largely unknown.
This is especially clinically concerning as HIV patients have an increased probability of
suffering from chronic pain (Marcus et al., 2000), and these opioid analgesic prescriptions
are increasing in this patient population (Miaskowski et al., 2016; Merlin et al., 2016).
In experiment 1 of the present study, we aimed to investigate the in vivo effects of
estradiol on HIV-1 Tat-mediated morphine reinforcement. To examine this, we
administered estradiol on a QOD (every other day) regimen and used the two-bottle choice
paradigm to assess morphine self-administration in ovariectomized female mice in
experiment 1. To assess morphine dependence, we precipitated withdrawal with the
nonselective opioid receptor antagonist, naloxone, in experiment 2. Shortly after naloxone
administration, we observed and quantified displays of withdrawal behaviors. In
5

experiment 1, we hypothesized that estradiol would potentiate HIV-1 Tat mediated
morphine reinforcement and later increase withdrawal behaviors in Experiment 2. In
experiment 3, we conducted a live/dead assay using differentiated SH-SY5Y human
neuroblastoma cells to assess whether oxycodone could potentiate the neurotoxic effects
of HIV-1 Tat in the absence of glial inputs. Furthermore, we investigated whether
physiological concentrations of estradiol (E2) and progesterone (P4) could attenuate Tatmediated neurotoxicity and whether they would retain their neuroprotective attributes
when oxycodone was present. Based on previous studies, we hypothesized that HIV-1 Tat
would increase the proportion of cell death and that oxycodone could potentiate these
effects. We anticipated that E2 and P4 would attenuate cell death in a dose-dependent
manner.
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2. Materials and Methods
The use of animals in these studies was preapproved by the Institutional Animal Care
and Use Committee (IACUC) at the University of Mississippi. All experiments were
conducted in accordance with ethical guidelines defined by the National Institutes of
Health (NIH Publication No. 85-23).
2.1. Subjects and housing
For the in vivo experiments, ovariectomized (OVX), Tat transgenic, female mice (n =
13/group) expressed (Tat+), or did not express (Tat-), the HIV-1 Tat1-86 protein in a
doxycycline-dependent manner (Paris et al., 2016; Gonek et al., 2018) and were assessed
for morphine preference using two-bottle choice and precipitated withdrawal. Animals
were housed in a temperature- and humidity- controlled environment on a reversed 12:12h
light-dark cycle (lights on at 09:00 h) with ad libitum access to food and water.
2.2. Experiment 1: Morphine Two-Bottle Choice
Ovariectomized mice were singly-housed and acclimated to two drinking bottles
filled with water for days 1-6. Drinking bottles were filled with 50 mL of water to habituate
mice to the procedure. Mice and bottles were weighed daily and values were recorded.
Bottles were replenished to 50 mL daily. On days 2-6 Tat expression was induced (or not)
via daily doxycycline injection (30 mg/kg, i.p.). On days 7-11, one bottle was filled with a
solution of quinine (0.1 mg/ml in water) and the other contained a solution of morphine
(0.3 mg/ml in water). Bottles and mice were weighed daily, and the placement of the bottles
in the cage was counterbalanced to obviate potential effects caused by a side-preference.
On the last day, mice were injected with the non-selective opioid receptor antagonist,
7

naloxone (1 mg/kg, i.p.) to precipitate withdrawal. To assess estradiol’s effect on morphine
preference, self-administration, and withdrawal behaviors, ovariectomized mice were
subcutaneously administered estradiol (0.09 mg/kg, s.c., QOD) throughout the study.
2.3. Experiment 2: Precipitated withdrawal
Mice were administered an injection of the opioid receptor antagonist, naloxone (1
mg/kg, s.c.), in order to precipitate withdrawal. Mice were singly-housed in a rectangular,
clear observation box (16 x 16 x 30 cm) and observed for 10 minutes. The proportion of
mice that jumped, latency to jumping, frequency of jumps, forepaw tremors, wet-dog
shakes, and fecal boli were recorded as indices of withdrawal (Fitting et al., 2016).
2.4. Experiment 3: Neurotoxicity of HIV-1 Tat and oxycodone
2.4.1. Chemicals
SH-SY5Y human neuroblastoma cells were treated with vehicle or a saturating dose
of oxycodone (500 nM in ddH20; Sigma-Aldrich, Saint Louis, MO), vehicle or low-to-high
physiological P4 (10 or 100 nM; Sigma-Aldrich) or E2 (1 or 10 nM; Sigma-Aldrich; Paris
et al., 2016) dissolved in DMSO and diluted 1:10,000 in media, and vehicle or HIV-1 Tat186

(100 nM diluted to concentration in ddH20; #1002-2, ImmunoDx, Woburn, MA) for 20

h prior to live/dead assessment. The concentration of Tat reflects one from a range that
elicits functional deficits in glia and neurons similar to those observed in HIV infection
(Kruman et al., 1998; Nath et al., 1999; Singh et al., 2004; El-Hage et al., 2005, 2008; Perry
et al., 2010). SH-SY5Y cells were differentiated via sequential exposure to retinoic acid
(1.5 mg/ml dissolved in 95% EtOH and protected from light; #R2625, Sigma-Aldrich) and
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BDNF (10 µg/ml dissolved in DMEM/F12; #SRP3014, Sigma-Aldrich) as described
below.
2.4.2. Cell Culture
Differentiated Human Neuroblastoma Cells (SH-SY5Y): SH-SY5Y neuroblastoma
cells were obtained from ATCC (#CRL-2266, Manassas, VA). Cells were seeded onto 24well plates at a density of 5×104/well for assessment of cell death. Prior to differentiation,
cells were maintained in growth media: 89.5% DMEM/F12 (#11320-033, Life
Technologies, Carlsbad, CA), 10% heat-inactivated fetal bovine serum (FBS;
#SH30071.03, Thermo Scientific Hyclone, Logan, UT), and 0.5% antibiotic/antimycotic
mixture (#15240-062, Life Technologies). One day after seeding, growth media was fully
exchanged for differentiation media #1 which contained retinoic acid diluted 1:500 in
growth media. After 24 hours in differentiation media #1, media was fully exchanged for
the serum-free differentiation media #2 consisting of BDNF diluted 1:200 in DMEM/F12
(supplemented only with the 0.5% antibiotic/antimycotic mixture). Cells were
differentiated and ready to undergo experimental manipulation the next day. On the day of
the experiment, dilutions were prepared to achieve the appropriate concentrations of
oxycodone (500 nM) and E2 (1 nM 10 nM), or P4 (10 nM,100 nM) prior to administration.
2.4.3. Live/Dead Assay
Briefly, experimental treatments were applied to differentiated SH-SY5Y cells
seeded on 24-well plates and live/dead assay was performed 20 h later. Prior work utilizing
time-lapsed microscopy (0-60 h) identified the 20 h time-point as the earliest time when
Tat- and pregnane steroid-treated cells significantly diverged on the measure of viability
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(Paris et al., 2016). To stain the cells for imaging, a working solution of propidium iodine
and Hoescht was prepared by diluting stocks in Hank’s Balanced Salt Solution (HBSS;
1:500 dilution). Media in the 24-well plates was replaced with HBSS containing propidium
iodide and Hoescht. Cells were imaged using a Nikon Ti-2 microscope and quantified using
ImageJ software. Viability of the cells was assessed by calculating the proportion of
necrotic cells [# propidium iodide+ cells / # total cells) *100].
2.5. Statistical analyses
In the two bottle choice experiment, liquid intake was assessed by measuring the
difference in daily bottle weight and assuming a density of 1 g/ml. Total liquid intake was
calculated by adding together the intake from both the test and control bottles, and
preference was calculated as follows: (test bottle intake) / (total liquid intake) *100. Drug
intake was calculated as: test bottle intake * test compound concentration (mg/ml) / daily
weight (kg). Preference and total liquid intake were analyzed via separate repeated
measures ANOVAs, and somatic signs of withdrawal were analyzed via separate two-way
ANOVAs. Live/dead analyses were assessed via separate three-way ANOVAs with
oxycodone condition, hormone condition, and Tat condition as factors. Fisher’s Protected
Least Significant Difference post-hoc tests determined group differences following main
effects. Interactions were delineated via simple main effects and main effect contrasts with
alpha controlled for multiple comparisons. Analyses were considered significant when p <
0.05. All statistical analyses were assessed via SAS StatView.
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3. Results
3.1. Experiment 1: Estradiol increased morphine preference and total liquid intake
To assess whether Tat increased morphine preference and self-administration
behaviors, and whether estradiol influences this, estradiol’s effect on morphine selfadministration behaviors, ovariectomized Tat induced (or not induced) mice were singlyhoused and given the choice to drink from 2 different bottles: one containing a solution of
quinine (0.1mg/ml in water) and the other containing a solution of morphine (0.3mg/ml
in water). On day 1, vehicle-administered Tat(+) mice showed a significantly greater
preference for the morphine solution than did vehicle-administered Tat(-) mice [F(2,42) =
5.78, p < 0.05] (Fig. 1A). However, all mice increased their preference for the morphine
solution during the following days (Fig. 1A, 1B). Further, estradiol significantly
increased total liquid intake in both Tat(+) and Tat(-) mice [F(2,42) = 13.787, p < 0.05]
(Fig. 1C), compared to vehicle mice (fig. 1D). Lastly, estradiol also significantly
increased consumption of morphine in all mice, irrespective of Tat exposure [F(2,42) =
13.787, p < 0.05](Fig. 1E) compared to vehicle administration (Fig. 1F).
3.2. Experiment 2: Tat or estradiol increased withdrawal behavior
The purpose of this experiment was to examine estradiol’s effect on morphinemediated withdrawal behaviors in ovariectomized mice. To precipitate withdrawal, mice
were administered an injection of naloxone, and the number jumps, latency to jump,
forepaw tremors, wet-dog shakes, and fecal boli were recorded and analyzed to quantify
withdrawal behaviors. Tat expression significantly increased jumping behavior compared
to Tat(-) controls [F(4,26) = 1.94, p < 0.05] (Fig. 2A), which is the primary indication of
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withdrawal within rodent models. Estradiol also significantly increased jumping behavior
in Tat (-) control mice [F(4,26 = 1.940, p = 0.017] (Fig. 2A). Notably, estradiol appeared
to attenuate jumping among Tat (+) mice, but this was not statistically significant (p =
0.07) (Fig. 2A). Additionally, estradiol appeared to attenuate the latency to jump, but this
did not reach significance (Fig. 2B).
3.3. Experiment 3: Neurotoxicity of HIV-1 Tat and oxycodone
3.3.1. Neuroprotective Effects of Estradiol on Tat-mediated Cytotoxicity
To assess the neuroprotective potential of estradiol on HIV-1 Tat-mediated cell
death, differentiated SH-SY5Y cells were treated with vehicle, oxycodone (500 nM), Tat
(100 nM), and/or E2 (1 nM or 10 nM). A three-way ANOVA revealed a significant
hormone condition x Tat condition interaction [F(2,155) = 3.36, p < 0.05] (Fig. 3A).
Exposure to Tat significantly increased the proportion of cell death compared to vehicletreated control wells (p = 0.0001). Irrespective of oxycodone administration, E2
administered at 1 nM (p = 0.047) or 10 nM (p = 0.026) significantly attenuated Tatmediated cell death. No additional effect of oxycodone was observed on cell viability.
3.3.2. Neuroprotective Effects of Progesterone on Tat-mediated Cytotoxicity
To assess the neuroprotective potential of progesterone on HIV-1 Tat-mediated cell
death, differentiated SH-SY5Y cells were treated with vehicle, oxycodone (500 nM), Tat
(100 nM), and/or P4 (10 nM or 100 nM). A three-way ANOVA revealed a significant
hormone condition × Tat condition interaction [F (2, 192) = 3.72, p < 0.05] (Fig. 3B).
Exposure to Tat significantly increased the proportion of cell death compared to vehicletreated control wells (p = 0.003). Irrespective of oxycodone administration, P4 administered
12

at 100 nM (p = 0.003) significantly attenuated Tat-mediated cell death. P4 administered at
10 nM failed to produce a significant attenuation of Tat-mediated cell death (p = 0.18, n.s.).
No additive effect of oxycodone was observed on cell viability.
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4. Discussion
The ﬁndings of Experiment 1 in the present study upheld the hypothesis that
estradiol would potentiate HIV-1 Tat-mediated morphine reinforcement in ovariectomized
mice. On the first day of morphine administration, Tat significantly increased the
acquisition of a morphine preference among vehicle-treated mice compared to Tat(-)
vehicle-administered controls. Interestingly, estradiol significantly increased, not only
morphine consumption, but total liquid intake as well, irrespective of Tat exposure. The
findings of Experiment 2 upheld the hypothesis that estradiol would increase withdrawal
behaviors. Tat expression significantly increased jumping behaviors in vehicleadministered mice. Similarly, E2 significantly increased jumping behaviors in Tat(-) mice.
Albeit, we noted the non-significant appearance of attenuated jumping behavior in Tat(+)
mice administered E2. Estradiol also non-significantly decreased the latency to jump for all
mice. Lastly, the aims of Experiment 3 were to determine whether oxycodone influenced
HIV-1 Tat-mediated neurotoxicity in differentiated SH-SY5Y cells, to investigate whether
administration of E2 and P4 would attenuate these neurotoxic effects, and whether these
neuroprotective attributes would be observed in a dose-dependent manner. The ﬁndings
from the present experiment upheld the hypothesis that exposure to HIV-1 Tat would
increase the proportion of cell death in differentiated SH-SY5Y human neuroblastoma
cells. Oxycodone did not potentiate HIV-1 Tat-mediated neurotoxicity. Additionally,
administration of E2 significantly attenuated Tat-mediated neurotoxicity at both
concentrations (1 nM, 10 nM). Administration of P4 only significantly attenuated Tatmediated neurotoxicity at the larger concentration (100 nM). These findings confirm and
extend previous work.

14

The current literature suggests that sex differences in the addiction cycle exist, yet
females remain underrepresented in addiction research. For example, preclinical studies
show that females tend to acquire self-administration faster and self-administer higher
amounts of drugs than do males (Lynch & Carroll, 1999). One factor that is thought to
underlie these gender disparities are sex hormones, specifically estradiol. In fact, studies
show that female rats will work harder for and self-administer higher doses of cocaine more
during the estrous phase, when estradiol is highest, than any other phase in the estrous cycle
(Roberts et al., 1989). Further, when ovariectomized rats are treated with estradiol, the
motivation to self-administer cocaine is enhanced (Lynch et al., 2001).Studies show that
estradiol may work in concert with the dopamine reward circuitry to potentiate the
rewarding properties of drugs, thus increasing their abuse potential in females (Becker,
1999; Yoest et al., 2014). Consistent with the current literature, we observed a significant
increase in morphine consumption among E2-treated subjects in the present study Though
it is important to note that we used ovariectomized mice in these experiments. The use of
ovariectomized animals allows the manipulation of hormones, but may also present a
potential caveat in that it could affect sensitivity to E2. Nonetheless, further investigation
is needed to determine estradiol’s behavioral effects in concert with opioids on the HIVpositive female population, as the effects of opioids are not well understood.
Substance abuse and HIV-1 infection are well recognized as comorbid epidemics.
Comorbid substance abuse has been known to reduce the time for HIV-1 patients to
develop neuroHIV symptoms, or even worsen the neurological complications of neuroHIV
(Bell et al., 2006). Past studies suggest that the infiltration of the dopaminergic system by
HIV-1 proteins such as Tat, and subsequent Tat-mediated dysfunction may underlie some
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of these symptoms (Fitting et al., 2015). As the dopaminergic system is responsible for
drug reward and reinforcement, this biologically implies that the presence of Tat may
possess some influence over the rewarding properties of certain drugs. Furthermore, this
effect may be observed in psychostimulant drugs, as one study revealed that HIV-1 Tatinduced mice display significant increases in cocaine-conditioned place preference, as well
as longer cocaine-induced hyperlocomotion than non-induced male mice (Paris et al.,
2014). Though this is apparent in psychostimulants, Tat’s behavioral effects in conjunction
with opioid drugs remain little known. Although, evidence from another study suggests
this potentiated effect may also be observed with morphine administration (Gonek et al.,
2018). In the present study, we observed a significant increase in morphine preference on
the first day of the two-bottle choice protocol in Tat-induced, ovariectomized female mice.
This finding suggests that Tat decreased the time to acquire morphine self-administration,
thus potentially alluding to Tat-mediated potentiation of the rewarding properties of
morphine.
A typical cycle of addiction commonly includes multiple periods of abstinence,
withdrawal, and subsequent relapse. Sex differences are still apparent in these late stages
of addiction as well. Some drugs cause women to experience worsened withdrawal
symptoms than men (Becker & Koob, 2016). Generally, females also experience greater
sensitivity to stress during the abstinence stage, which may explain the higher tendency of
women to relapse compared to men (Hudson & Stamp, 2011). These effects remain
consistent when modeled in animals (Becker & Koob, 2016). However, HIV-1 Tat and
estradiol’s concurrent effect on morphine dependence are poorly understood. In the current
study, we aimed to measure this by utilizing a precipitated withdrawal procedure. In this
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experiment, we observed a significant Tat-mediated increase in the jumping behaviors of
morphine dependent mice. Estradiol further increased these jumping behaviors in control
mice; while displaying a tendency to decrease these jumping behaviors in Tat-induced
mice. These findings suggest that Tat and estradiol may potentiate morphine dependence
when administered and expressed separately; however, potentially protective interactions
between estradiol and Tat cannot be ruled out. This finding could likely be in agreement
with in vitro studies of estradiol neuroprotection, but further examination is needed.
HIV-1

associated

neurocognitive

deficits

are

partly

mediated

by

neuroinflammation in the CNS due to an upregulation of cytokines caused by viral HIV-1
proteins. This neuroinflammation contributes to the neurotoxicity of HIV-1 Tat. However,
there is evidence that pregnane and estrane hormones may be able to protect against this
neurotoxicity. For example, an in vitro study revealed that allopregnanolone (a metabolite
of P4) can protect against the neurotoxic effects of HIV-1 Tat in neuronal-glial co-cultures,
while also attenuating the increase of microglial activation caused by exposure to Tat (Paris
et al., 2016, 2020). The present study was conducted on neuroblastoma cells in the absence
of glial inputs in order to parse the effects on neuron without Tat-potentiation of gliallymediated cytokine production. E2 significantly attenuated Tat-mediated cell death at both
concentrations (1 nM, 10 nM), while P4 significantly attenuated cell death at the larger
concentration (100 nM). Though the 10 nM concentration of P4 did not produce a
significant effect, there appeared to be a trend that led to less cell death in this condition.
These findings were consistent with evidence from past studies that suggest that estrane
and pregrane have neuroprotective qualities (Kendall, 2005; Wallace et al., 2006). These
data from the current study and past studies suggest that these steroid hormones may

17

ameliorate the prevalence of neurocognitive deficits by attenuating the neurotoxic effects
of HIV proteins such as Tat. More studies should be conducted to further investigate their
neuroprotective qualities.
The intertwined epidemics of intravenous drug use and new HIV-1 cases caused by
injection drug use significantly increases the urgency to understand the interaction between
opioids and HIV-1. Findings in the current literature of opioid’s effects on HIV-1 are
discrepant. Some studies suggest that opioids, such as morphine, may have protective
qualities against HIV-1 in vivo (Donahoe et al., 2009). Other studies suggest that morphine
stimulates replication of viral HIV proteins (Schweitzer et al., 1991), and also interacts
with HIV-1 Tat to potentiate its neurotoxic effects in vitro (Fitting et al., 2014). Effects of
opioids can be biphasic, exerting different actions acutely vs. those observed chronically.
In support, opioids are initially immunosuppressive, but promote a profound immune
response in withdrawal (Gonek et al., 2018). Though opioid-HIV interactions have now
been the subject of research for nearly 20 years, interactions between oxycodone, a
commonly prescribed opioid analgesic, and HIV-1 remain under-investigated. This
interaction is important to understand due to the higher prevalence of long-term opioid
usage among HIV patients (Silverberg et al., 2012). In the current study, oxycodone in
combination with HIV-1 Tat did not elicit any significant effects or interactions in
differentiated SH-SY5Y cells. However, one limitation is that this interaction was solely
examined in neuronal cells. Previous literature suggests that glia cells are critical to opiate
responses (El-Hage et al., 2008; Hauser et al., 2012). This suggests that further
investigation is warranted to determine whether these results will remain consistent in glial
cells.

18

In sum, these data further demonstrate HIV-1 Tat’s ability to modulate the
behavioral effects of morphine addiction. Tat was shown to potentiate morphine selfadministration acquisition and dependence; however, its presence did not interact in vitro
with oxycodone when glia was absent. Additionally, estradiol increased morphine selfadministration behavior despite Tat condition, and increased jumping behaviors in Tat (-)
control mice. Interestingly, E2 displayed protective qualities by decreasing jumping
behaviors when administered to Tat-induced, ovariectomized female mice. Further,
estradiol, as well as progesterone, also displayed neuroprotective properties in culture by
ameliorating Tat-mediated neurotoxicity. These findings suggest that E2 may possess
protective qualities at the cellular level, but caution must be taken when considering its
capacity to increase opioid reinforcement at the behavioral level.
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Figure 1A. Morphine preference in vehicle groups. On the first day of morphine
administration, Tat significantly increased morphine preference in non-estradiol (E2)
administered mice (p < 0.05; n = 13/group).

Figure 1B. Morphine preference in the estradiol group. There were no significant effects
of estradiol on morphine preference (n = 13/group).
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Figure 1C. Total liquid intake in vehicle groups. There were no significant effects on
liquid intake on mice that received vehicle treatments (n = 13/group).

Figure 1D. Total liquid intake in estradiol groups. Estradiol significantly increased liquid
intake irrespective of Tat condition (p < 0.05; n = 13/group).
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Figure 1E. Amount of morphine consumed in vehicle groups. There were no significant
effects on morphine consumption in vehicle mice (n = 13/group).

Figure 1F. Amount of morphine consumed in estradiol groups. Estradiol administration
significantly increased morphine consumption, irrespective of Tat condition (p < 0.05; n =
13/group).
34

Figure 2A. Percent jumping in vehicle and estradiol groups. Tat significantly increased
jumping behaviors in non-estradiol (E2) administered mice (p < 0.05). Estradiol
significantly increased jumping behavior in Tat (-) mice (p = 0.017), and non-significantly
attenuated jumping behavior in Tat (+) mice (p = 0.0669; n = 13/group).

Figure 2B.
Latency to jump in
vehicle and estradiol groups. Estradiol non-significantly reduced latency to jump (p = 0.09;
n = 13/group).
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Cell Viability

Figure 3A. Estradiol live/dead assay. Estradiol (E2) significantly attenuated Tat-mediated
neurotoxicity at 1nM (p = 0.047) and 10 nM concentrations (p = 0.03; n = 13-14).

Cell Viability

Figure 3B. Progesterone live/dead assay. Progesterone (P4) significantly attenuated Tatmediated cell death only at 100 nM concentration (p = 0.003; n = 17).
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